Delårsrapport Q2

Under första hälften av 2021 har Fluicell gjort viktiga framsteg på flera viktiga områden, inte minst genom lanseringen av Biozone 6®, försäljningen av Biopixlar till National Institutes of Health (NIH) och initierandet av forsknings och utvecklingsprogrammet BioRej™ Advance inom regenerative medicin.

Delårsrapport Q2 2021

 

During the first half of 2021, Fluicell has made several important advancements across multiple different important areas, not least through the launch of Biozone 6®, the sale of Biopixlar to the National Institutes of Health (NIH) and the initiation of the regenerative medicine research and development program BioRej™ Advance.

Delårsrapport Q2 2021

 

An edited English version of the CEO words from the Q2 report is available through our CEO Newsletter, which you can access using the button below.

Fluicell CEO Newsletter